Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of HRS4800 in healthy males
NCT04573036Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-4800 in pain (6 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Part 1 - HRS4800 Single Dose Escalation - Safety at 14 days and Part 2 - HRS4800 Food Effect at 21 days. Started Nov 2020; status: completed.
02
Drugs
HRS-4800
03
Conditions
pain
Beyond the preview
Go deeper on NCT04573036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04573036.